NEWS

January 13, 2023
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 9, 2023
Travere Therapeutics Provides Corporate Update and 2023 Outlook
January 3, 2023
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 14, 2022
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 16, 2022
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 15, 2022
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
November 9, 2022
Travere Therapeutics to Present at Upcoming Investor Conferences
October 27, 2022
Travere Therapeutics Reports Third Quarter 2022 Financial Results
October 26, 2022
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
October 20, 2022
Travere Therapeutics to Report Third Quarter 2022 Financial Results
October 13, 2022
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
October 13, 2022
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy